These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7709404)

  • 1. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients.
    Cocozza M; Picano T; Oliviero U; Russo N; Coto V; Milani M
    Stroke; 1995 Apr; 26(4):597-601. PubMed ID: 7709404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiaggregatory effects of picotamide in long-term treatment: a 2-year, double-blind placebo-controlled trial.
    Cocozza M; Milani M; Picano T; Oliviero U; Russo N; Coto V
    Vasc Med; 1997 Nov; 2(4):292-5. PubMed ID: 9575601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients.
    Giustina A; Perini P; Desenzani P; Bossoni S; Ianniello P; Milani M; Davì G; Romanelli G
    Diabetes; 1998 Mar; 47(3):423-30. PubMed ID: 9519749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study.
    Coto V; Oliviero U; Cocozza M; Milani M
    J Int Med Res; 1998; 26(4):200-5. PubMed ID: 9818786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study.
    Milani M; Longoni A; Maderna M
    Br J Clin Pharmacol; 1996 Dec; 42(6):782-5. PubMed ID: 8971437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
    Vetrano A; Milani M; Corsini G
    G Ital Cardiol; 1999 May; 29(5):524-8. PubMed ID: 10367219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group.
    Balsano F; Violi F
    Circulation; 1993 May; 87(5):1563-9. PubMed ID: 8491012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of picotamide in the reduction of cardiovascular events in diabetic patients.
    Celestini A; Violi F
    Vasc Health Risk Manag; 2007; 3(1):93-8. PubMed ID: 17583179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of picotamide in long-term treatment of intermittent claudication.
    Coto V; Cocozza M; Oliviero U; Lucariello A; Picano T; Coto F; Cacciatore L
    Angiology; 1989 Oct; 40(10):880-5. PubMed ID: 2679241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term administration of picotamide on baseline and exercise-induced urinary albumin excretion in patients with type II diabetes mellitus and incipient nephropathy.
    Giustina A; Ianniello P; Bossoni S; Comini MT; Desenzani P; Gazzoli N; Romanelli G
    Clin Ther; 1994; 16(2):191-9. PubMed ID: 8062315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Picotamide: prevention and therapy of diabetic vasculopathies. A double-blind clinical study].
    Pibiri L; Petruzzo P; De Giudici A; Brotzu G
    Clin Ter; 1990 May; 133(4):233-7. PubMed ID: 2142911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinico-instrumental evaluation of the efficacy of picotamide in treating chronic obstructive arteriopathies of the lower extremities].
    Canonico V; Ammaturo V; Guarini P; Tedeschi C; Nunziata G; Nappi A; Forgione L; Rengo F
    Minerva Cardioangiol; 1991 Mar; 39(3):75-80. PubMed ID: 1881558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
    Neri Serneri GG; Coccheri S; Marubini E; Violi F;
    Eur Heart J; 2004 Oct; 25(20):1845-52. PubMed ID: 15474700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs.
    Neirotti M; Molaschi M; Ponzetto M; Macchione C; Poli L; Bonino F; Fabris F
    Angiology; 1994 Feb; 45(2):137-41. PubMed ID: 8129189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.
    Sagripanti A; Ferretti A; Nicolini A; Carpi A
    Biomed Pharmacother; 1996; 50(8):376-82. PubMed ID: 8952859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
    Markus HS; Droste DW; Kaps M; Larrue V; Lees KR; Siebler M; Ringelstein EB
    Circulation; 2005 May; 111(17):2233-40. PubMed ID: 15851601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study.
    Pogliani E; Milani M
    J Int Med Res; 1996; 24(3):311-5. PubMed ID: 8725994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Picotamide does not interfere with the anticoagulant activity of warfarin in patients wearing heart valve prostheses].
    Parise P; Gresele P; Viola E; Ruina A; Migliacci R; Nenci GG
    Clin Ter; 1990 Dec; 135(6):479-82. PubMed ID: 2151435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of picotamide in patients with vascular diseases].
    Speziale F; Taurino M; Colella E; Rizzo L; Fiorani P
    Recenti Prog Med; 1989 May; 80(5):271-5. PubMed ID: 2762664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pycnogenol® and Centella asiatica in the management of asymptomatic atherosclerosis progression.
    Belcaro G; Ippolito E; Dugall M; Hosoi M; Cornelli U; Ledda A; Scoccianti M; Steigerwalt RD; Cesarone MR; Pellegrini L; Luzzi R; Corsi M
    Int Angiol; 2015 Apr; 34(2):150-7. PubMed ID: 25519846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.